Sabby Management’s Biodexa Pharmaceuticals BDRX Stock Holding History

Sabby Management’s Portfolio BDRX Stock Details BDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$159K	Buy	51,494 +13,362	+35%	+$94K	0.35%	16
2025 Q4	$433K	Buy	+38,132	New	+$1.09M	0.62%	15

Other funds holding BDRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

HHCP

Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Sabby Management's BDRX Position: Q1 2026 in Review

Sabby Management increased its Biodexa Pharmaceuticals (BDRX) stake by 35% in Q1 2026, buying an estimated $94K and bringing the position to 51,494 shares worth $159K. The position accounts for 0.35% of the portfolio, ranked #16.

Sabby Management first reported a position in BDRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $433K in Q4 2025. 7 funds tracked by Wall St. Rank hold BDRX as of Q1 2026.

Sabby Management held 51,494 shares of Biodexa Pharmaceuticals worth $159K as of Q1 2026.
Sabby Management bought 13,362 Biodexa Pharmaceuticals shares in Q1 2026, an estimated $94K.
Biodexa Pharmaceuticals made up 0.35% of Sabby Management's portfolio in Q1 2026, its #16 holding.
Sabby Management first reported a position in Biodexa Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
Sabby Management's Biodexa Pharmaceuticals position peaked at $433K in Q4 2025.
7 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q1 2026.

Based on Sabby Management's 13F filing for Q1 2026, filed 15 May 2026.